Graham Nicholls joins Almac as director of biostatistics

Company: Almac Group

Brings more than 15 years of experience in the biopharmaceutical industry

Almac’s Clinical Technologies business unit has appointed Graham Nicholls as director of biostatistics.

Nicholls possesses more than 15 years of experience in the biopharmaceutical industry, serving in a variety of capacities including biostatistics, product management and client account management.

He will head Almac’s biostatistical department and will be responsible for consulting with clients on trial design, randomisation and drug supply strategies, adaptive trial implementation, and the application of statistical methods to improve clinical trial management.

Nicholls spent several years at GlaxoSmithKline as a senior statistician, HIV/infectious diseases and close to 10 years at Clinphone and Perceptive Informatics.

You may also like

Manufacturing

Almac’s Charnwood facility receives FDA approval for oral dose development and manufacturing

The facility, which focuses on the manufacture of high potency oral dosage forms, has been approved for use by the FDA
Sustainability

Almac Group signs virtual power purchase agreement for renewable energy

The integration of renewable energy will cut the company’s global scope 2 carbon emissions by 46%
Manufacturing

Almac completes “outstanding” grade by the KTP

The Innovate UK-funded KTP aimed to embed flow technologies to ensure long term security of supply for key raw materials through development
Manufacturing

Almac Sciences Ireland secures HPRA certification

This additional certification enables Almac to perform biologics testing for the determination of product quality attributes
Regulatory

Almac receives product approval by MHRA and Health Canada

The company’s site provides a range of solutions for blister packs, stickpacks, and kitting
Manufacturing

Almac Pharma Services to showcase high potent processing solutions at Manufacturing Chemist Live

Almac Pharma Services’ VP Operations & Charnwood Site Head, James Hurst, will join the event’s expert line up of speakers and share insight into developing a framework for the design of contained high potent solid oral dose processes
Research & Development

Towards the enzymatic synthesis of oligonucleotides: part II

By early 2020, ten oligonucleotide drugs had received US FDA regulatory approval; with many more in the pipeline, it’s only fair to say that this drug class is becoming big business
Subscribe now